Micron Biomedical announced today that it added $3 million to its Series A, bringing the total funding to $17 million.
Atlanta-based Micron develops dissolvable, microarray-based products to simplify the delivery of drugs and vaccines. J2 Ventures provided the additional $3 million. J2 Ventures Partner Dr. Matt Goldman joins Micron’s board as an observer following the financing. Goldman previously served as chief medical officer for the Defense Innovation Unit of the U.S. Defense Dept.
The company initially announced the Series A funding, led by Global Health Investment Corporation and LTS Lohmann, in November 2022. GRA Venture Fund also participated.
Get the full story at our sister site, Drug Delivery Business News.